Last reviewed · How we verify
A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe
The objective of this study is to evaluate the potential PK interaction between ABT-335, atorvastatin 80 mg and ezetimibe 10 mg when administered concurrently.
Details
| Lead sponsor | Abbott |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 18 |
| Start date | 2008-04 |
Conditions
- Pharmacokinetics
Interventions
- ABT-335
- Atorvastatin
- Ezetimibe
Primary outcomes
- PK interaction — Study duration approximately 62 days
Countries
United States